An inherited life-threatening arrhythmia model established by screening randomly mutagenized mice

Proc Natl Acad Sci U S A. 2024 Apr 23;121(17):e2218204121. doi: 10.1073/pnas.2218204121. Epub 2024 Apr 15.

Abstract

Inherited arrhythmia syndromes (IASs) can cause life-threatening arrhythmias and are responsible for a significant proportion of sudden cardiac deaths (SCDs). Despite progress in the development of devices to prevent SCDs, the precise molecular mechanisms that induce detrimental arrhythmias remain to be fully investigated, and more effective therapies are desirable. In the present study, we screened a large-scale randomly mutagenized mouse library by electrocardiography to establish a disease model of IASs and consequently found one pedigree that exhibited spontaneous ventricular arrhythmias (VAs) followed by SCD within 1 y after birth. Genetic analysis successfully revealed a missense mutation (p.I4093V) of the ryanodine receptor 2 gene to be a cause of the arrhythmia. We found an age-related increase in arrhythmia frequency accompanied by cardiomegaly and decreased ventricular contractility in the Ryr2I4093V/+ mice. Ca2+ signaling analysis and a ryanodine binding assay indicated that the mutant ryanodine receptor 2 had a gain-of-function phenotype and enhanced Ca2+ sensitivity. Using this model, we detected the significant suppression of VA following flecainide or dantrolene treatment. Collectively, we established an inherited life-threatening arrhythmia mouse model from an electrocardiogram-based screen of randomly mutagenized mice. The present IAS model may prove feasible for use in investigating the mechanisms of SCD and assessing therapies.

Keywords: animal model; catecholaminergic polymorphic ventricular tachycardia; forward genetics; inherited arrhythmia syndrome; ryanodine receptor 2.

MeSH terms

  • Animals
  • Arrhythmias, Cardiac / genetics
  • Death, Sudden, Cardiac
  • Flecainide
  • Mice
  • Mutation
  • Mutation, Missense
  • Ryanodine Receptor Calcium Release Channel / metabolism
  • Tachycardia, Ventricular*

Substances

  • Ryanodine Receptor Calcium Release Channel
  • Flecainide